RhumbLine Advisers’s Silk Road Medical, Inc. Common Stock SILK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-58,016
| Closed | -$1.57M | – | 4375 |
|
|
2024
Q2 | $1.57M | Buy |
58,016
+5,327
| +10% | +$111K | ﹤0.01% | 2014 |
|
|
2024
Q1 | $965K | Buy |
52,689
+1,324
| +3% | +$21K | ﹤0.01% | 2266 |
|
|
2023
Q4 | $630K | Sell |
51,365
-1,259
| -2% | -$11.8K | ﹤0.01% | 2528 |
|
|
2023
Q3 | $789K | Buy |
52,624
+84
| +0.2% | +$1.75K | ﹤0.01% | 2342 |
|
|
2023
Q2 | $1.71M | Buy |
52,540
+2,317
| +5% | +$84.6K | ﹤0.01% | 1997 |
|
|
2023
Q1 | $1.97M | Buy |
50,223
+2,021
| +4% | +$98.9K | ﹤0.01% | 1809 |
|
|
2022
Q4 | $2.55M | Buy |
48,202
+4,530
| +10% | +$221K | ﹤0.01% | 1652 |
|
|
2022
Q3 | $1.97M | Buy |
43,672
+3,501
| +9% | +$151K | ﹤0.01% | 1772 |
|
|
2022
Q2 | $1.46M | Buy |
40,171
+4,564
| +13% | +$166K | ﹤0.01% | 1939 |
|
|
2022
Q1 | $1.47M | Buy |
35,607
+1,584
| +5% | +$55.8K | ﹤0.01% | 1962 |
|
|
2021
Q4 | $1.45M | Sell |
34,023
-472
| -1% | -$23.6K | ﹤0.01% | 2046 |
|
|
2021
Q3 | $1.9M | Buy |
34,495
+1,353
| +4% | +$70.8K | ﹤0.01% | 1935 |
|
|
2021
Q2 | $1.59M | Buy |
33,142
+3,378
| +11% | +$172K | ﹤0.01% | 2055 |
|
|
2021
Q1 | $1.51M | Sell |
29,764
-2,297
| -7% | -$128K | ﹤0.01% | 2025 |
|
|
2020
Q4 | $2.02M | Sell |
32,061
-156
| -0.5% | -$9.68K | ﹤0.01% | 1840 |
|
|
2020
Q3 | $2.17M | Sell |
32,217
-12,203
| -27% | -$666K | ﹤0.01% | 1638 |
|
|
2020
Q2 | $1.86M | Buy |
44,420
+24,895
| +128% | +$956K | ﹤0.01% | 1772 |
|
|
2020
Q1 | $615K | Buy |
19,525
+2,627
| +16% | +$105K | ﹤0.01% | 2080 |
|
|
2019
Q4 | $682K | Buy |
16,898
+5,338
| +46% | +$187K | ﹤0.01% | 2237 |
|
|
2019
Q3 | $376K | Buy |
11,560
+4,843
| +72% | +$193K | ﹤0.01% | 2454 |
|
|
2019
Q2 | $326K | Buy |
+6,717
| New | +$286K | ﹤0.01% | 2568 |
|
Other funds holding SILK
RhumbLine Advisers's SILK Position: Q3 2024 in Review
RhumbLine Advisers sold out of Silk Road Medical, Inc. Common Stock (SILK) in Q3 2024, closing a stake of 58,016 shares — an estimated $1.57M sold.
RhumbLine Advisers first reported a position in SILK in Q2 2019 and held it in 21 quarters. The position peaked at $2.55M in Q4 2022. 1 fund tracked by Wall St. Rank holds SILK as of Q3 2024.
- RhumbLine Advisers reported no remaining Silk Road Medical, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- RhumbLine Advisers sold 58,016 Silk Road Medical, Inc. Common Stock shares in Q3 2024, an estimated $1.57M.
- RhumbLine Advisers first reported a position in Silk Road Medical, Inc. Common Stock in Q2 2019 and held it in 21 quarters.
- RhumbLine Advisers's Silk Road Medical, Inc. Common Stock position peaked at $2.55M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Silk Road Medical, Inc. Common Stock as of Q3 2024.
Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.